ASSEMBLY BIOSCIENCES, INC. (ASMB) earnings date
Mar 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 40 days, typically, give or take 18 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | after close | 43 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Mar 19, 2026 | after close | 78 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | after close | 41 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Thu, Mar 20, 2025 | after close | 79 | 8-K |
| Q3 FY2024 | Thu, Nov 7, 2024 | after close | 38 | 8-K |
What they guided beta
| Q3 FY2026 | "EX-99.1 Exhibit 99.1 Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates – Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection – – Exercised 40% U.S. Profit-Share option for the HSV helicase primase inhibitor program – – Received first $75 million collaboration extension fee from Gilead; cash runway projected into 2029 – SOUTH SAN FRANCISCO, Calif. – November 12, 2026 – Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseas" exhibit |
| Q3 FY2026 | "“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year,” said Jason Okazaki, chief executive officer and president of Assembly Bio." exhibit |
| Q3 FY2026 | "The company’s cash position, together with the $75 million collaboration extension fee received from Gilead in November 2026 following the third anniversary of the collaboration agreement, is projected to fund operations into 2029." exhibit |
| Q1 FY2026 | "Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights – Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 – SOUTH SAN FRANCISCO, Calif. – May 7, 2026 – Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for th" exhibit |
| Q1 FY2026 | "“As we look ahead, we anticipate receiving Gilead’s development plan and budget for the herpesvirus program and will evaluate our cost and profit share opt-in decision by mid-2026 while continuing to advance ABI-6250 toward Phase 2 in hepatitis delta virus by year-end.”" exhibit |
| Q1 FY2026 | "Initiation of a Phase 2 clinical study for ABI-6250 in participants with chronic hepatitis delta virus (HDV) infection expected in the fourth quarter of 2026" exhibit |
| Q1 FY2026 | "The company’s cash position is projected to fund operations into 2028." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ASMB
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ASMB
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ASMB/"><img src="https://veritasdata.dev/embed/ASMB.svg" alt="ASMB earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ASMB/)
Script
<script async src="https://veritasdata.dev/embed/ASMB.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ASMB"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.